Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study

This cross-sectional study conducted at 10 sites in China involved 1,254 patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with CDK4/6 inhibitors. The study assessed adverse events (AEs) and quality of life (QoL) from both patient and physician perspectives. Dalpiciclib was associated with the lowest incidence of increased liver enzymes and diarrhea compared to other inhibitors, and patients reported fewer side effects such as fatigue, alopecia, and nausea. Regarding QoL, hair loss was a significant concern, but dalpiciclib users reported the least distress, particularly those treated for over 6 months. Overall, dalpiciclib demonstrated the best safety profile and patient satisfaction among the CDK4/6 inhibitors studied.